BioSpace looks at some of the top stories from Day 2 of the virtual JP Morgan Annual Healthcare Conference.
If you are not happy with the results below please do another search
50 search results for:
The microscopic organisms living in our intestines may influence the severity of Covid-19 and the body’s immune response to it, and could account for lingering symptoms, researchers reported.
Johnson & Johnson is on track to roll out a single-shot coronavirus vaccine in March, and plans to have clear data on how effective it is by the end of January or early February, the U.S. healthcare company’s chief science officer said.
Flagship Pioneering launched a new company called Inzen Therapeutics, which will discover and develop a new class of medicines based on a new area of biology that will provide new therapeutic approaches to multiple types of diseases.
Fishawack Health, a leading global commercialization partner for the life sciences industry, announced the acquisition of StoneArch, a Minneapolis-based healthcare marketing agency renowned for strategic, creative and storytelling capabilities.
The U.S. Food and Drug Administration accepted for priority review a Biologics License Application (BLA) for Merck’s 15-valent pneumococcal conjugate vaccine V114.
Moncef Slaoui, the GlaxoSmithKline vaccines veteran who has helmed the federal government’s Operation Warp Speed Covid-19 vaccine program, is stepping down from the role ahead of the inauguration of President-elect Joe Biden.
The second year of the Covid-19 pandemic may be tougher than the first given how the new coronavirus is spreading, especially in the northern hemisphere as more-infectious variants circulate, the World Health Organization (WHO) said.
Amgen is partnering with Ann Arbor, Michigan-based EVOQ Therapeutics for a license and collaboration deal to discover and develop drugs for autoimmune disorders.
U.S. firm Johnson & Johnson is likely to apply for EU approval for the company’s Covid-19 vaccine candidate in February, a top lawmaker said.